DK0654037T3 - Enantiomere anti-retrovirus-nukleotidanaloger - Google Patents

Enantiomere anti-retrovirus-nukleotidanaloger

Info

Publication number
DK0654037T3
DK0654037T3 DK93918659T DK93918659T DK0654037T3 DK 0654037 T3 DK0654037 T3 DK 0654037T3 DK 93918659 T DK93918659 T DK 93918659T DK 93918659 T DK93918659 T DK 93918659T DK 0654037 T3 DK0654037 T3 DK 0654037T3
Authority
DK
Denmark
Prior art keywords
enantiomeric
nucleotide analogues
retroviral nucleotide
compounds
retroviral
Prior art date
Application number
DK93918659T
Other languages
Danish (da)
English (en)
Inventor
Antonin Holy
Hana Dvorakova
Erik Desire Alice Declercq
Jan Marie Rene Balzarini
Original Assignee
Rega Stichting
Acad Of Science Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rega Stichting, Acad Of Science Czech Republic filed Critical Rega Stichting
Application granted granted Critical
Publication of DK0654037T3 publication Critical patent/DK0654037T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6521—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK93918659T 1992-08-05 1993-08-04 Enantiomere anti-retrovirus-nukleotidanaloger DK0654037T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/925,610 US6057305A (en) 1992-08-05 1992-08-05 Antiretroviral enantiomeric nucleotide analogs
PCT/US1993/007360 WO1994003467A2 (en) 1992-08-05 1993-08-04 Antiretroviral enantiomeric nucleotide analogs

Publications (1)

Publication Number Publication Date
DK0654037T3 true DK0654037T3 (da) 1999-11-01

Family

ID=25451994

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918659T DK0654037T3 (da) 1992-08-05 1993-08-04 Enantiomere anti-retrovirus-nukleotidanaloger

Country Status (12)

Country Link
US (3) US6057305A (cs)
EP (2) EP0654037B1 (cs)
JP (2) JP4083691B2 (cs)
AT (1) ATE179983T1 (cs)
CA (2) CA2141589C (cs)
CZ (2) CZ293533B6 (cs)
DE (1) DE69324923T2 (cs)
DK (1) DK0654037T3 (cs)
ES (1) ES2131116T3 (cs)
GR (1) GR3030754T3 (cs)
SG (1) SG47761A1 (cs)
WO (1) WO1994003467A2 (cs)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
JPH09506333A (ja) * 1993-09-17 1997-06-24 ギリアード サイエンシーズ，インコーポレイテッド 治療化合物の投薬方法
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
IT1270008B (it) * 1994-09-23 1997-04-16 Ist Superiore Sanita Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CN1078593C (zh) * 1995-06-15 2002-01-30 三菱化学株式会社 核苷酸磷酸酯衍生物
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CN101239989B (zh) * 1996-07-26 2012-12-12 吉联亚科学股份有限公司 核苷酸类似物
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
DE69831694T2 (de) * 1997-07-25 2006-07-13 Gilead Sciences, Inc., Foster City Nukleotid-Analog Zusamensetzung und Synthese Verfahren
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
EP1243593B1 (en) * 1997-07-25 2005-09-21 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
CN1307421C (zh) 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
US6339151B1 (en) 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
JP2003525866A (ja) 1999-07-22 2003-09-02 ニューバイオティックス インコーポレイテッド 治療抵抗性腫瘍を処置するための方法
WO2001044257A1 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
EA004926B1 (ru) 2000-07-21 2004-10-28 Джилид Сайэнс, Инк. Пролекарственные соединения фосфонатных аналогов нуклеотидов (варианты), способ их получения, способ скрининга для их идентификации и содержащая их композиция, способ антивирусной терапии или профилактики
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
IL159494A0 (en) 2001-06-29 2004-06-01 Acad Of Science Czech Republic 6-2'-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
WO2003028737A1 (en) * 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20050033051A1 (en) * 2001-11-14 2005-02-10 Babu Yarlagadda S Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
JP5280631B2 (ja) 2003-06-16 2013-09-04 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック 抗ウイルスヌクレオチド類似物としてのホスホネート基を有するピリミジン化合物
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
WO2006066074A2 (en) * 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
JP2008538771A (ja) * 2005-04-25 2008-11-06 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック テロメラーゼのプロセッシビティーを向上させるための化合物の使用
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007068934A2 (en) * 2005-12-14 2007-06-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
JP5597391B2 (ja) 2006-04-04 2014-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キナーゼ拮抗剤
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US20080318904A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched tenofovir
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
JP5547099B2 (ja) * 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
CN102177172A (zh) * 2008-07-02 2011-09-07 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
BR112012024661A2 (pt) 2010-04-01 2015-09-15 Centre Nat Rech Scient composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2011156416A1 (en) 2010-06-11 2011-12-15 Gilead Sciences, Inc. Topical antiviral formulations for prevention of transmission of hsv-2
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112013014485B1 (pt) 2010-12-10 2021-03-30 Sigmapharm Laboratories, Llc Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
SG191897A1 (en) 2011-01-10 2013-08-30 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9650346B2 (en) 2011-04-08 2017-05-16 Laurus Labs Private Ltd. Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
MX2013011820A (es) * 2011-05-10 2014-02-28 Okapi Sciences Nv Compuestos para su uso en el tratamiento de infecciones retrovirales de los felinos.
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
EP2780348B1 (en) 2011-11-16 2017-03-01 Laurus Labs Private Limited Process for the preparation of tenofovir
EP2794624B1 (en) * 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
LT2970346T (lt) 2013-03-15 2018-11-26 The Regents Of The University Of California Acikliniai nukleozido fosfonato diesteriai
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN104230934B (zh) * 2013-06-08 2016-12-28 上海医药工业研究院 一种化合物及其制备方法和用途
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
CN103641857B (zh) * 2013-12-20 2016-08-24 石药集团中诺药业（石家庄）有限公司 一种替诺福韦新晶型及其制备方法
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
AU2015317972B2 (en) 2014-09-15 2019-10-17 The Regents Of The University Of California Nucleotide analogs
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
SMT202100592T1 (it) 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017281797A1 (en) 2016-06-24 2019-01-24 Infinity Pharmaceuticals, Inc. Combination therapies
PH12022550371A1 (en) 2017-12-07 2023-05-03 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN115677774B (zh) * 2021-07-23 2025-04-22 上海医药工业研究院有限公司 膦酸酯衍生物及其制备方法和用途
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB544419A (en) * 1940-01-08 1942-04-13 Union Special Machine Co Improvements in or relating to sewing machines
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4221910A (en) * 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
WO1984004748A1 (en) * 1983-05-24 1984-12-06 Stanford Res Inst Int Novel antiviral agents
PT78769A (en) * 1983-06-24 1984-07-01 Merck & Co Inc Process for preparing (s)-9-(2,3-dihydroxy-1-propoxymethyl)guanine and derivatives thereof useful as antiviral agents
US4556727A (en) * 1984-07-18 1985-12-03 University Patents, Inc. Ferroelectric smectic liquid crystals
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
AU613592B2 (en) * 1986-11-18 1991-08-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosophonomethoxy-alkyene purine and pyrimide derivatives
DE3883070T2 (de) * 1987-05-18 1994-01-27 Canon Kk Polymer-Flüssigkristallzusammensetzung und Flüssigkristallvorrichtung.
JP2580205B2 (ja) * 1987-10-21 1997-02-12 チッソ株式会社 光学活性−２−ビフェニリルピリジン類
FI95567C (fi) * 1987-12-25 1996-02-26 Daiichi Seiyaku Co Propoksibentseenijohdannaisia ja menetelmä niiden valmistamiseksi
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
AU4376589A (en) * 1988-11-07 1990-05-10 Gist-Brocades N.V. Optically active benzoxazines and benzothiazines
DE3906357A1 (de) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
PT97407B (pt) * 1990-04-20 1998-08-31 Rega Stichting Processo para a preparacao de (r)-9-{2-(fosfono-metoxi)-propil}-guanina
CZ285420B6 (cs) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
CS276072B6 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
WO1992002511A1 (en) * 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
DE10399025I2 (de) * 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
CA2190862A1 (en) * 1994-05-31 1995-12-07 Bo Oberg Post exposure prevention of hiv

Also Published As

Publication number Publication date
WO1994003467A3 (en) 1994-06-23
ES2131116T3 (es) 1999-07-16
JP2008120820A (ja) 2008-05-29
EP0654037A1 (en) 1995-05-24
JP3561272B2 (ja) 2004-09-02
CA2141589A1 (en) 1994-02-17
CZ27295A3 (en) 1995-12-13
US6479673B1 (en) 2002-11-12
JP4083691B2 (ja) 2008-04-30
CA2141589C (en) 2007-04-17
GR3030754T3 (en) 1999-11-30
CZ293533B6 (cs) 2004-05-12
JPH08503927A (ja) 1996-04-30
SG47761A1 (en) 1998-04-17
CA2574904C (en) 2009-06-16
WO1994003467A2 (en) 1994-02-17
US6057305A (en) 2000-05-02
CZ290797B6 (cs) 2002-10-16
DE69324923T2 (de) 1999-11-25
EP0897917A1 (en) 1999-02-24
ATE179983T1 (de) 1999-05-15
JP2004189750A (ja) 2004-07-08
EP0654037B1 (en) 1999-05-12
HK1011998A1 (en) 1999-07-23
US6653296B1 (en) 2003-11-25
DE69324923D1 (de) 1999-06-17
CA2574904A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
DK0654037T3 (da) Enantiomere anti-retrovirus-nukleotidanaloger
ATE108452T1 (de) Puringruppen enthaltende cyclobutane.
DE69001187D1 (de) 6-epifumagillole, ihre herstellung und ihre verwendung.
OA09470A (en) 2-substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof.
NL300241I1 (nl) Hydroxymethyl(methyleencyclopentyl)uurines en -pyrimidines.
SE8500307L (sv) Nya, antiviruella medel
FI852974A0 (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
DE3851179D1 (de) Oxetanocin.
ES2131730T3 (es) Preparacion de compuestos de guanina n-9 sustituidos.
ES2108016T3 (es) Triazolopiridazinas substituidas.
KR930703253A (ko) 고리형 화합물
ES2055211T3 (es) Purinil- y pirimidinil-tetrahidrofuranos.
DE68909143D1 (de) Prostaglandin-Vorläufer und ihre Herstellung.
ATE176242T1 (de) Uck14-verbindungen
ATE108767T1 (de) Acyclische terpene.
DK0717731T3 (da) Antivirale difluorstatonanaloge
ATE53029T1 (de) Phenylharnstoff-herbicide.